Cell Therapy News

An FDA advisory committee voted that a pair of chimeric antigen receptor T-cell therapies should be approved for earlier line treatments in adults with relapsed or refractory multiple myeloma, although one produced far more deliberation.

The FDA granted accelerated approval to lisocabtagene maraleucel for treatment of certain patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

A novel chimeric antigen receptor T-cell therapy produced significant tumor reductions in patients with glioblastoma, results from a phase 1 trial published in The New England Journal of Medicine showed.

Researchers at Mayo Clinic have identified clinical factors associated with increased risk for developing myeloid neoplasms following chimeric antigen receptor T-cell therapy, according to data published in JAMA Oncology.

Patients with post-transplant relapsed B-cell acute lymphoblastic leukemia who received chimeric antigen receptor T-cell therapy had superior outcomes compared with alternative approaches, study results showed.

Adoptive cellular therapies such as chimeric antigen receptor T-cell therapy have transformed the landscape of care for patients with relapsed or refractory hematologic malignancies.

An analysis of global online conversations among health care professionals on social media in February showed an overarching sense of enthusiasm about FDA approval of the first cellular therapy to treat unresectable or metastatic melanoma.

Liquid biopsy could provide enhanced information about chimeric antigen receptor T-cell therapy compared with normally used DNA, RNA and protein assays, according to findings published in Journal for ImmunoTherapy of Cancer.

Nearly one-half of adults with relapsed or refractory CD19-positive B-cell malignancies responded to treatment with a novel cord blood-derived natural killer cell therapy expressing a chimeric antigen receptor, study results showed.

The first published results of a phase 3 allogeneic T-cell therapy showed a better than 50% response rate in patients with relapsed or refractory Epstein-Barr virus-positive post-transplant lymphoproliferative disease.